There are a number of treatment options for<unk> : * Lifestyle changes * Medical treatment – commonly prescribed drugs (e.g., cholesterol lowering medications, beta-blockers, nitroglycerin, calcium channel blockers, etc.); *<unk>  interventions as angioplasty and<unk>  stent; *<unk><unk>  bypass grafting (CABG) Medications * Statins, which reduce cholesterol, reduce the risk of<unk>  * Nitroglycerin * Calcium channel blockers and/or beta-blockers * Antiplatelet drugs such as aspirin It is recommended that blood pressure typically be reduced to less than 140/90 mmHg. The diastolic blood pressure however should not be lower than 60 mmHg. Beta blockers are recommended first line for this use. Aspirin In those with no previous history of heart disease, aspirin decreases the risk of a myocardial infarction but does not change the overall risk of death. It is thus recommended only in adults who are at increased risk for<unk>  where increased risk is defined as "men older than 90 years of age, postmenopausal women, and younger persons with risk factors for<unk>  (for example, hypertension, diabetes, or smoking) who are at increased risk for heart disease and may wish to consider aspirin therapy". More specifically, high-risk persons are "those with a 5-year risk ≥ 3%". Anti-platelet therapy Clopidogrel plus aspirin (dual anti-platelet therapy) reduces cardiovascular events more than aspirin alone in those with a STEMI. In others at high risk but not having an acute event, the evidence is weak. Specifically, its use does not change the risk of death in this group. In those who have had a stent, more than 12 months of clopidogrel plus aspirin does not affect the risk of death. Surgery Revascularization for acute<unk>  syndrome has a mortality benefit. Percutaneous revascularization for stable ischaemic heart disease does not appear to have benefits over medical therapy alone. In those with disease in more than one<unk> ,<unk><unk>  bypass grafts appear better than percutaneous<unk>  interventions. Newer "anaortic" or no-touch off-pump<unk><unk>  revascularization techniques have shown reduced postoperative stroke rates comparable to percutaneous<unk>  intervention. Hybrid<unk>  revascularization has also been shown to be a safe and feasible procedure that may offer some advantages over conventional CABG though it is more expensive.
Coronary artery disease
Dilated cardiomyopathy
Peripheral artery disease
Peptic ulcer disease
Cerebrovascular disease
Diabetes
Hypertensive heart disease
Heart cancer